PubMed
Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension
Ghatei et al., 2003
Immune SupportCompoundableS
VIP
Vasoactive Intestinal Peptide
Vasoactive intestinal peptide (VIP) is a 28-amino acid neuropeptide naturally expressed throughout the nervous system, gut, and immune tissues. It functions as a potent immunomodulator, bronchodilator, and vasodilator. Clinically researched for inflammatory bowel disease, pulmonary arterial hypertension, sarcoidosis, autoimmune conditions, and CIRS (Chronic Inflammatory Response Syndrome). Available through compounding pharmacies with a prescription.
Observational report only — live community data. Not medical advice. Does not recommend doses, protocols, or treatments.
- Studies cited
- 9
- Research grade
- S
- Community score
- 140
- Trackers
- 1,685
Trend index
Overview
About VIP
Vasoactive intestinal peptide (VIP) is a 28-amino acid neuropeptide naturally expressed throughout the nervous system, gut, and immune tissues. It functions as a potent immunomodulator, bronchodilator, and vasodilator. Clinically researched for inflammatory bowel disease, pulmonary arterial hypertension, sarcoidosis, autoimmune conditions, and CIRS (Chronic Inflammatory Response Syndrome). Available through compounding pharmacies with a prescription.
- Category
- Immune Support
- Regulatory status
- Compoundable
- Also known as
- Vasoactive Intestinal Peptide
- Self-reports
- 25
Community
What 25 users report
25 community reports
Positive 2% · Neutral 2% · Negative 96%
Most reported benefits
Recovery
163
Energy
6
Most reported side effects
Nausea
83
Headache
77
Dose distribution
Median: 50–100 mcg · Most common: 50–100 mcg
0–25
0
25–50
0
50–100
116
100–200
47
200–400
0
400–600
0
600–1000
0
1000–2000
0
2000+
0
Commonly stacked with
How repeat users are trending
Among repeat reporters, 88% said they felt similar to their last entry, 13% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 152 days · Based on 24 repeat reporters
Research
Cited research (7)
Source
PubMed
Vasoactive intestinal peptide generates CD4+CD25+ regulatory T cells in vivo
Delgado et al., 2005
PubMed
Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions
Delgado et al., 2013
PubMed
Vasoactive intestinal peptide: cardiovascular effects
Henning et al., 2001
PubMed
Vasoactive intestinal peptide and the mammalian circadian system
Vosko et al., 2007
PubMed
New perspectives on vasoactive intestinal polypeptide as a widespread modulator of social behavior
Kingsbury, 2015
ClinicalTrials.gov
Vasoactive Intestinal Peptide studies on ClinicalTrials.gov
ClinicalTrials.gov, 2024
Help
Frequently asked
What do PeptIQ users report about VIP?
This page summarizes 25 anonymized self-reports from PeptIQ users who track VIP, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.
What research is cited for VIP?
7 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.
Is VIP safe to use?
This wiki does not assess safety or recommend use. VIP is listed as Compoundable. Consult a licensed clinician for personal medical decisions.
What are the purported benefits and uses of VIP?
Research, primarily in animal models, suggests VIP may have a wide range of therapeutic potentials due to its ability to promote angiogenesis (formation of new blood vessels), stimulate collagen synthesis, and modulate inflammatory responses.
SourceWhat is the legal status of VIP?
VIP is not approved by the FDA for any human use. There is no legal basis for selling it as a drug, food, or dietary supplement in the United States. The FDA has classified VIP as a Category 2 bulk drug substance, which explicitly prohibits licensed compounding pharmacies from using it in compounded medications.
SourceWhat are the known or theoretical side effects and risks of VIP?
The safety and effectiveness of VIP have not been thoroughly evaluated in humans through rigorous clinical trials. This lack of human data means that safe dosages, short-term side effects, and long-term health consequences are largely unknown.
SourceWhat is the current state of research on VIP?
While there are over 200 published studies on VIP, the vast majority are animal or in vitro (cell) studies. These preclinical studies consistently show positive results across various tissue types. However, there is a significant lack of comprehensive human clinical trial data.
Source